Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Dose 2

Phase 1Biologic

UUniversity of Minnesota

Dose 2 is one of 39 biologic programs targeting Melanoma. It is currently in Phase 1.

2

Indications

3

Total Trials

2

Active Trials

38

Competitors

Pipeline

Status by Indication[3][1]

Indication

MelanomaActive, not recruiting

Safety IssuesEnrolling by invitation

MelanomaPhase 1

Active, not recruiting

Safety IssuesPhase 1

Enrolling by invitation

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Tecentriq

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

CC 5013

Bristol-Myers Squibb

Methylphenidate Hydrochloride

Bempegaldesleukin

NNektar Therapeutics

Adjuvant Therapy

FFudan University

Anti-PD1

Interferon-Alpha-2a

Zelboraf

CConrado Roberto Hoffmann Filho

Intron a

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 1Active, not recruiting

Melanoma

NCT01586403

Clinical

Trials by Indication[1]

Melanoma1 trial

Transfer of Genetically Engineered Lymphocytes in Melanoma Patients

Active, not recruiting·LLoyola University·Phase 1·NCT01586403·14 enrolled

Vitamin D1 trial

Vitamin D Levels Following Topical Application of Vitamin D Ointment

Completed·UUniversity of Minnesota·Phase 1·NCT02676674·10 enrolled

Safety Issues1 trial

A Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of ETD-001 Gel in Healthy Chinese Subjects

Enrolling by invitation·EEtern Therapeutics Wuxi Limited·Phase 1·NCT07674862·56 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Dose 2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dose 2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dose 2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Minnesota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: UUniversity of Minnesota

Related News